Amphastar Pharmaceuticals Inc (AMPH) Receives Average Rating of “Hold” from Analysts

Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) have been given a consensus rating of “Hold” by the ten analysts that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $19.20.

Several brokerages recently commented on AMPH. Needham & Company LLC lifted their price target on shares of Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, September 27th. BidaskClub raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday. Piper Jaffray Companies set a $19.00 price objective on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, October 22nd. Jefferies Group set a $19.00 price objective on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, October 29th. Finally, Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down $0.09 during trading hours on Friday, reaching $19.37. 111,964 shares of the company traded hands, compared to its average volume of 185,277. Amphastar Pharmaceuticals has a 12-month low of $12.05 and a 12-month high of $19.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. The firm has a market cap of $890.55, a price-to-earnings ratio of 129.67, a P/E/G ratio of 1.36 and a beta of 1.69.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The firm had revenue of $57.90 million for the quarter, compared to analyst estimates of $57.23 million. During the same period last year, the business earned $0.14 EPS. Amphastar Pharmaceuticals’s revenue for the quarter was down 9.8% compared to the same quarter last year. research analysts anticipate that Amphastar Pharmaceuticals will post -0.03 EPS for the current fiscal year.

In other Amphastar Pharmaceuticals news, Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction on Thursday, October 26th. The shares were sold at an average price of $18.39, for a total transaction of $144,582.18. Following the transaction, the director now directly owns 31,978 shares of the company’s stock, valued at approximately $588,075.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO William J. Peters sold 6,226 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $19.67, for a total transaction of $122,465.42. The disclosure for this sale can be found here. Insiders have sold a total of 72,787 shares of company stock worth $1,359,684 over the last three months. 11.10% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of AMPH. GSA Capital Partners LLP purchased a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $400,000. Argent Capital Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 102.6% in the third quarter. Argent Capital Management LLC now owns 121,275 shares of the company’s stock valued at $2,167,000 after acquiring an additional 61,425 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its holdings in shares of Amphastar Pharmaceuticals by 1.8% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 283,200 shares of the company’s stock valued at $5,060,000 after acquiring an additional 5,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Amphastar Pharmaceuticals by 17.0% in the third quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock valued at $27,844,000 after acquiring an additional 226,271 shares in the last quarter. Finally, Nordea Investment Management AB boosted its holdings in shares of Amphastar Pharmaceuticals by 11.6% in the third quarter. Nordea Investment Management AB now owns 129,046 shares of the company’s stock valued at $2,306,000 after acquiring an additional 13,439 shares in the last quarter. 44.14% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/19/amphastar-pharmaceuticals-inc-amph-receives-average-rating-of-hold-from-analysts.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply